Emcure Pharmaceuticals is a leading Indian pharmaceutical company engaged in developing, manufacturing, and globally marketing a wide range of pharmaceutical products across several major therapeutic areas.
Known for being research and development (R&D) driven, Emcure boasts a differentiated product portfolio that includes orals, injectables, and biotherapeutics. This has enabled the company to reach target markets across over 70 countries, with a strong presence in India, Europe, and Canada.
Product Portfolio and Revenue
Emcure’s revenue is significantly driven by sales of iron, chiral, biotherapeutics, injectables, and photochemistry products, which contributed 52.97% of their domestic sales in FY2024.
The company focuses on pharmaceutical products used in chronic and sub-chronic therapeutic areas, which are expected to grow faster than acute areas over the next five years. Chronic therapeutic areas contributed ₹25,460.48 million, or 46.22%, of their total Domestic Sales for the MAT Financial Year 2024.
Objectives of the Issue
- Repayment and/or prepayment of certain outstanding borrowings.
- General corporate purposes.
Emcure Pharmaceuticals IPO Dates and Price Band
| Parameter | Value |
|---|---|
| IPO Open | July 3, 2024 |
| IPO Close | July 5, 2024 |
| IPO Size | Approx ₹1952.03 Crores (19,365,346 Equity Shares) |
| Fresh Issue | Approx ₹800 Crores (7,936,507 Equity Shares) |
| Offer for Sale | Approx ₹1152.03 Crores (11,428,839 Equity Shares) |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹960 to ₹1008 Per Share |
| Listing | BSE & NSE |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | ₹90 Per Share |
Market Lot
- Minimum Lot: 14 shares (₹14,112)
- Maximum Lot for Retail Investors: 196 shares (₹197,568)
- S-HNI Minimum Lot: 210 shares (₹211,680)
- B-HNI Minimum Lot: 994 shares (₹10,01,952)
Key Dates
- Basis of Allotment: July 8, 2024
- Refunds: July 9, 2024
- Credit to Demat Account: July 9, 2024
- IPO Listing Date: July 10, 2024
Financial Performance
| Year | Revenue (₹ Crores) | Expense (₹ Crores) | PAT (₹ Crores) |
|---|---|---|---|
| 2022 | ₹5918.86 | ₹4946.31 | ₹702.56 |
| 2023 | ₹6031.72 | ₹5278.36 | ₹561.85 |
| 2024 | ₹6715.24 | ₹5978.08 | ₹527.58 |
Emcure Pharma IPO GMP Today
- Emcure Pharmaceuticals’ IPO is generating buzz, with a grey market premium (GMP) of +₹299 today, as per investorgain.com. This indicates a strong interest, as shares are trading at a ₹299 premium in the grey market.
- Factoring in the upper end of the IPO price band and the current GMP, Emcure Pharma’s expected listing price is ₹1,307 per share. This marks a 29.66% increase over the IPO price of ₹1,008.
- The grey market premium reflects investors’ enthusiasm and their willingness to pay a premium above the issue price.
Valuation Metrics (FY2024)
- Earning Per Share (EPS): ₹27.54 per Equity Share
- Return on Net Worth (RoNW): 16.87%
- Net Asset Value (NAV): ₹163.22 per Equity Share
Peer Group
- Dr. Reddy’s Laboratories Limited
- Cipla Limited
- Alkem Laboratories Limited
- Torrent Pharmaceuticals Limited
- Mankind Pharma Limited
- Abbott India Limited
- J. B. Chemicals & Pharmaceuticals Limited
Application Process
Investors can apply for Emcure Pharmaceuticals IPO via ASBA through their bank accounts or by downloading IPO forms from NSE and BSE websites.
FAQs
What is Emcure Pharma IPO?
The Emcure Pharma IPO offers 19,365,346 equity shares at ₹960 to ₹1008 per share. The minimum order quantity is 14 shares.
When Emcure Pharma IPO will open?
The Emcure Pharma IPO will open for subscription on July 3, 2024.
When Emcure Pharma IPO will Close?
The Emcure Pharma IPO will close for subscription on July 5, 2024.
How much does the company plan to raise through the IPO?
Emcure Pharma plans to raise Rs 1952 crore through the IPO.
Avinash Dyal